Company* | Product | Description | Indication | Status (Date) |
|
||||
AUTOIMMUNE |
||||
Amgen Inc. | Enbrel | Etanercept; tumor | Psoriatic | European Commission approved the marketing authorization application for Enbrel (12/17) |
Dimethaid | Pennsaid | Product that uses | Osteoarthritis | Company received an approvable letter from Health Canada (12/3) |
Genelabs | Prestara | Prasterone, GL701; the | Systemic lupus erythematosus | Genelabs submitted a marketing authorization application in Europe (12/23) |
CANCER |
||||
Adherex | Exherin | Member of a new class | Cancer | Company received Canadian regulatory approval to begin a Phase I trial (12/9) |
Aphton Corp. | G17DT | Anti-gastrin immunogen | Gastric cancer | Australian authorities granted orphan drug status for Immunogen, which automatically gives the drug priority evaluation (12/19) |
CENTRAL NERVOUS SYSTEM |
||||
Cephalon | Provigil | Modafinil tablets; oral | Excessive | Company received marketing approval from the UK to expand the label of Provigil to treat excessive daytime sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (12/3) |
Orphan | Xyrem | Sodium oxybate oral | Narcolepsy | The Committee for Orphan Medicinal Products recommended orphan drug designation in Europe for Xyrem (12/13) |
INFECTION |
||||
Avant | Cholera- | Cholera vaccine | Cholera | Company began a Phase II trial in about 70 adult and 280 pediatric subjects in Bangladesh (12/12) |
MISCELLANEOUS |
||||
Pain | -- | Drug to test the idea | Irritable | Company initiated a pilot study in Israel with 50 patients (12/18) |
| ||||
Notes: |
||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. |
||||
TSE = Toronto Stock Exchange |